GlassScriptPhysician profile
Timothy R Kirk
NPI 1578618047
$367.67
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.60 · 2020: $96.27 · 2021: $117 · 2022: $104.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $62.49 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.97 | 2020-2021 | |
| Alcon Vision LLC | $44.52 | 2019-2020 | |
| Coopervision INC. | $44.18 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $40.18 | 2019-2020 | |
| Dompe US, INC. | $23.97 | 2021 | |
| Kala Pharmaceuticals, INC. | $22.68 | 2021 | |
| Sun Pharmaceutical Industries INC. | $21.05 | 2021 | |
| Oyster Point Pharma, INC. | $19.45 | 2022 | |
| Allergan, INC. | $18.79 | 2021 | |
| Abbvie INC. | $17.39 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.